Skip to main content

LabCorp Offers $925M in Senior Notes

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America said after the close of the market Tuesday that it is offering $925 million in senior notes.

It intends to use the proceeds to fund part of its purchase of Genzyme Genetics. The $925 million all cash deal was announced in September.

Funds from the offering will also go toward general corporate use, the company said.

The offering consists of two tranches: $325 million of 3.125 percent notes due 2016, and $600 million of 4.625 percent notes due 2020. The notes will bear interest from Nov. 19, 2010, payable semi-annually on May 15 and Nov. 15, beginning May 15, 2011.

The notes will be unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt, the company said.

The active joint book-running manager for the offering is Citigroup Global Markets. Barclays Capital and Merrill Lynch, Pierce, Fenner & Smith are passive joint book-running managers. The offer is subject to market and other conditions.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.